Kolon TissueGene, Inc. (KOSDAQ:950160)

Market Cap	3.58T
Revenue (ttm)	5.15B
Net Income (ttm)	-35.85B
Shares Out	81.60M
EPS (ttm)	-452.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	396,601
Average Volume	319,605
Open	44,000
Previous Close	43,700
Day's Range	43,000 - 45,500
52-Week Range	13,190 - 59,300
Beta	-0.78
RSI	56.47
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950160

Financial Performance

In 2024, Kolon TissueGene's revenue was 5.07 billion, an increase of 36.90% compared to the previous year's 3.71 billion. Losses were -33.80 billion, 96.2% more than in 2023.